BioSpace

BioSpace is a leading platform for life science news, career opportunities, and industry insights. Founded in 1985 as a directory of life science organizations, it has grown into a vital hub connecting innovative companies with professionals across the sector. Today, BioSpace serves millions in the global life sciences community, providing up-to-date news, expert resources, and recruitment tools. With relationships reaching two-thirds of the U.S. life science workforce and thousands of new subscribers each month, BioSpace helps companies make informed talent decisions and amplify their presence through webinars, podcasts, articles, advertising, and job postings. Headquartered in Des Moines, Iowa, with a distributed team across North America and beyond, BioSpace remains a privately owned company dedicated to advancing health and quality of life worldwide.

Articles: 722

BioSpace

27 Aug 2025, 12:10

Biotechnology

Regeneron Eyes 2026 Filing For siRNA Myasthenia Gravis Drug After Phase III Win

Regeneron’s cemdisiran, used alone or in combination with its complement inhibitor Veopoz, significantly improved activities of daily living in patients with generalized myasthenia gravis.

BioSpace

27 Aug 2025, 10:21

Biotechnology

Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change

Eli Lilly drops a second Phase III readout for orforglipron; AbbVie committed to the psychedelic therapeutics space with the $1.2 billion acquisition of Gilgamesh’s depression asset; the CDC taps vaccine skeptic Retsef Levi to lead its COVID-19 immunization working group; and the FDA prioritizes overall survival in cancer drug development.

BioSpace

27 Aug 2025, 04:21

Biotechnology

Generate’s Chief IP ‘Geek’ Wants To Answer AI’s Biggest Legal Questions

Generate:Biomedicines’ Nicole Clouse is one of the key legal minds trying to understand who owns what AI creates. The answers are critical to the future of biotech.

BioSpace

27 Aug 2025, 04:06

Biotechnology

Pharma Spent More Than $48B in China in H1, Eclipsing Total 2024 Haul

If the trend holds, IQVIA expects 2025 deal volume between Chinese and multinational companies to easily eclipse the 100 agreements signed in 2024.

BioSpace

26 Aug 2025, 13:17

Biotechnology

Lilly Plots Path to FDA After Second Phase III Readout for Orforglipron

While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition," they also pointed to a manufacturing advantage that could unlock a “double-digit billion dollar opportunity” for Eli Lilly.

BioSpace

26 Aug 2025, 12:55

Biotechnology

Argenx Eyes ‘Broadest Label’ for Vyvgart in Myasthenia Gravis After Positive Phase III Data

Based on new data, argenx expects to file for the expansion of Vyvgart’s label into patients with generalized myasthenia gravis who are negative for antibodies against the AChR marker—an indication William Blair analysts called the broadest option in this disease space.

BioSpace

26 Aug 2025, 09:55

Biotechnology

Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations

Closely watched data from Eli Lilly and Viking Therapeutics this month have reignited the discussion around oral weight-loss drugs—and their ultimate place within the anti-obesity medication market.

BioSpace

25 Aug 2025, 04:01

Biotechnology

Weight-Loss Wasteland: 5 Obesity Assets That Failed

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and losers. Here are five molecules that never made it to the market.

BioSpace

22 Aug 2025, 14:36

Biotechnology

Which Weight Loss Treatments Will Be Most Effective?

While it’s impossible to make apples-to-apples comparisons of the many obesity candidates with so many differences across clinical trials, we at BioSpace are giving it our best shot.

BioSpace

22 Aug 2025, 14:22

Biotechnology

Oral Obesity Candidates Disappoint With Novo Emerging as Leader of the Pack

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” investors, William Blair’s Andy Hsieh predicts weight loss pills will play a bigger role in low- and middle-income countries than in the U.S.

BioSpace

22 Aug 2025, 12:07

Biotechnology

Krystal Cuts Melanoma Study of Viral Immunotherapy as FDA ‘Uncertainty’ Muddies Approval Pathway

Krystal Biotech's decision follows the FDA’s rejection last month of Replimune’s RP1, which works similarly to Krystal Biotech’s KB707. The biotech said this has introduced “heightened uncertainty” regarding a potential accelerated pathway for the candidate.

BioSpace

20 Aug 2025, 05:01

Biotechnology

With Prasad Back at FDA, Capricor To Fight CRL for DMD Cardiomyopathy

Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the regulator that it got it wrong. Capricor plans to resubmit the application based on deramiocel’s existing dataset.

BioSpace

19 Aug 2025, 14:03

Biotechnology

Viking Crashes as Obesity Pill Delivers Over 12% Weight Loss

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile marred the results.

BioSpace

19 Aug 2025, 12:00

Biotechnology

Oral Wegovy’s Pending Approval Puts Spotlight on Viability of High-Dose Peptides

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured investors it has the manufacturing capacity to roll out oral semaglutide without restrictions on supply.

BioSpace

18 Aug 2025, 13:13

Biotechnology

Pfizer’s $5.4B GBT Bet Disappoints Again as Sickle Cell Therapy Fails in Phase III

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain episodes in patients with sickle cell disease over the 48-week treatment period.

BioSpace

14 Aug 2025, 14:43

Biotechnology

Eli Lilly Keeps Obesity Pipeline Fresh with $1.3B Superluminal Partnership

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new small molecule obesity medications for Lilly.

BioSpace

14 Aug 2025, 13:04

Biotechnology

Schrödinger Cans Early-Stage Blood Cancer Drug After Two Patient Deaths

After two patients who received the investigational CDC7 blocker died, pushing forward with SGR-2921’s development would be “difficult,” according to Schrödinger, whose stock dropped 17.5% before the opening bell on Thursday.

BioSpace

14 Aug 2025, 12:57

Biotechnology

2025 Chikungunya Outbreak: A Global Health Challenge

BioSpace

14 Aug 2025, 12:06

Biotechnology

CytomX Reports Treatment-Related Patient Death in Phase I Colorectal Cancer Study

The death was linked to acute kidney injury in a patient who had a single kidney remaining and a “complex medical history,” according to CytomX.

BioSpace

13 Aug 2025, 12:22

Biotechnology

Sarepta Provides New Elevidys Safety Data, Reveals Zero Ambulatory Deaths

Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory patients with Duchenne muscular dystrophy.

BioSpace

11 Aug 2025, 12:57

Biotechnology

140-Year-Old Boehringer Ingelheim Dives Into Cancer With NSCLC Nod

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

BioSpace

11 Aug 2025, 10:00

Biotechnology

The Future of Cell and Gene Therapy: Navigating Innovation, Regulation, and Manufacturing Challenges

An interview with Philip Vanek, chief commercialization officer of the International Society for Cell & Gene Therapy (ISCT), reveals both promising developments and significant concerns shaping the advanced therapies sector's trajectory through 2025 and beyond. This interview was conducted with support from Tozaro.

BioSpace

11 Aug 2025, 05:01

Biotechnology

Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light

In the wake of multiple patient deaths from liver injuries related to Sarepta Therapeutics’ AAV gene therapy platform, some in the sector are looking for ways to improve the current technology, while others are eager to move on.

BioSpace

11 Aug 2025, 05:01

Biotechnology

Opinion: Antagonism to mRNA Technology Is Killing Our Best Shot At a Cure For Cancer

The recent announcement of RFK Jr.’s termination of mRNA vaccine contracts is the latest effort to undermine this promising technology at the federal level. Pharmaceutical companies and private investors must fill the gap and ensure that research into this critical resource continues.

BioSpace

11 Aug 2025, 04:01

Biotechnology

5 Oral Obesity Drugs Challenging Lilly’s Orforglipron

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

BioSpace

07 Aug 2025, 12:45

Biotechnology

Lilly’s Hotly Anticipated Oral Weight Loss Drug Delivers Lukewarm Results in Phase III

Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ bear scenario for the oral med.

BioSpace

06 Aug 2025, 13:49

Biotechnology

Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market

Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.

BioSpace

06 Aug 2025, 04:01

Biotechnology

Building Pharma’s Farm System: Eli Lilly, Boehringer Ingelheim, More Invest in the Future

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and venture funds to uncover cutting-edge scientific trends, determine their future focus points and even carve out a niche in an emerging geographical hotspot.

BioSpace

05 Aug 2025, 12:52

Biotechnology

Praxis’ Seizure Drug Demonstrates ‘Impressive’ Efficacy in Mid-Stage Trial

Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that of its closest competitors.

BioSpace

05 Aug 2025, 12:43

Biotechnology

Report of Patient Deaths Sends Agios Shares Seesawing

While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an SEC filing midday Monday that the drug’s risk-benefit profile remains unchanged.

BioSpace

04 Aug 2025, 12:38

Biotechnology

Allogene Scraps Immunosuppressive Antibody After Patient Death in Lymphoma Trial

The pivotal Phase II trial is testing Allogene’s CAR T candidate cemacabtagene ansegedleucel for large B-cell lymphoma. ALLO-647 was being used as a preparative lymphodepletion therapy.

BioSpace

04 Aug 2025, 04:03

Biotechnology

Glioblastoma Funding Rises as Nonprofits Drive Interest and Pharma Returns to the Table

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma research is entering a new phase spurred by smarter trials, targeted funding and renewed interest from companies like Merck and Jazz Pharmaceuticals.